VBI Vaccines — Investor Presentation (February 2023)
41 slides from VBI Vaccines's investor presentation, Feb 28, 2023

Slide 1: Corporate Overview February 2023
W7 BS \y MIN\\\ VBI Zmyy —— VACCINES ACTIVATING THE POWER WITHIN Corporate Overview February 2023

Slide 2: Forward-Looking & Safe Harbor Statements
i N %, Forward-Looking & Safe Harbor Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forwa

Slide 3: About VBI: Immune to Limitations
About VBI : Immune to Limitations Ih our inn 5) approach to virus-like particles, our vision is to” Cuplsetisiintits We are a biotechnology company driven by fe A importance of protecting ie and enhancing human life rything Ina ary human immune system to target and overcome significant, aggressive,

Slide 4: The Science of Virus-Like Particles (VLPs)
The Science of Virus-Like Particles (VLPs) Transforming natural immunity into potent protection and treatment = > _— Virus-Like Particles Enveloped Virus-Like Particles Antigenic Protein Lipid Bilayer - VBI's Proprietary Platform Technology - Sub-unit vaccines with no infectious material <._ _- @VLP

Slide 5: VBI's Portfolio: Both Sides of the Fight
VBI's Portfolio : Both Sides of the Fight VBI's broad portfolio is designed to power the immune system to prevent and treat disease Approved Prophylactic Vaccine repaiwseie) —« Preevbrio™™ vr A LN Prophylactic Candidates Cytomegalovirus (CMV) —_VBF-1501 evo [I COVID-19 (Ancestral) VBI-2902 (monovale

Slide 6: Notable Recent Accomplishments Prepare VBI for a Transformative 2023
Notable Recent Accomplishments Prepare VBI for a Transformative 2023 First US, EU, & Canadian Approval Advancement & Expansion of Pipeline wm, VCD) 8 Financial | ms O} Strong Financia + PreHevbrio™ (Hepatitis 8 Vaccine [Recombinant]) approved by the FDA in Nov. 2021, added to the ACIP list of recomm

Slide 7: PreHevbrio Hepatitis B Vaccine (Recombinant)
VU PreHevbrio Hepatitis B Vaccine (Recombinant)

Slide 8: PreHevbrio is the Only 3-Antigen HBV Vaccine
PreHevbrio is the Only 3-Antigen HBV Vaccine PreHevbrio is scientifically differentiated from other HBV vaccines — expressing the three a B surface antigens (S, pre-SI, and pre-S2), and manufactured in mammalian cells (vs. yeast! PreHevbrio: ze Pre-Sl Antigen @o The pre-SI and pre-S2 regions of the

Slide 9: More Adults Achieved Seroprotection with PreHevbrio in Phase 3 Studies
More Adults Achieved Seroprotection with PreHevbrio in Phase 3 Studies PROTECT Phase 3 Study CONSTANT Phase 3 Study 2-arm safety and immunogenicity study N=1607 aduits aged 18-90 years ‘Seroprotection Rate! (SPR) 4 Weeks After Receiving the 3% Dose of PreHevbrio or Engerix-B @ Pretievorio @ Engerix-

Slide 10: Hepatitis B Remains a Persistent Public Health Problem
Hepatitis B Remains a Persistent Public Health Problem —— U.S. & Europe : HBV Disease Burden and Challenges HBV infection is the most common blood-borne infection, with an estimated 240M- 350M chronically-infected individuals worldwide Suboptimal surveillance results in under-representation of true

Slide 11: Public Health Bodies are Changing Tactics
Public Health Bodies are Changing Tactics, Bringing Renewed Prioritization in the Fight to Eliminate HBV Changing U.S. Adult HBV Vaccination Guidelines * In November 2021, the CDC’s Advisory Committee on Immunization Practices (ACIP) unanimously voted to move from a risk-based HBV adult vaccination

Slide 12: Commercialization & Upcoming Milestones
Commercialization & Upcoming Milestones Commercialization Partnerships : Cc + vBl entered into a full end-to-end commercialization partnership with Syneos Health in 2019 to support the US. Syn eos launch of PreHevbrio™, including VBI-dedicated leadership, medical, market access, cind sales teams Hea

Slide 13: Hepatitis B (HBV) Therapeutic Candidate: VBI-2601
IW zB BS = (Hepatitis B (HBV) \) Therapeutic Candidate : VBI-2601 B

Slide 14: Current Chronic Hepatitis B Landscape
Current Chronic Hepatitis B Landscape Chronic HBV infection represents a critical unmet public health need and an opportunity for meaningful innovation to achieve a functional cure Global chronic HBV (cHBV) unmet need: + Over 290 million adults + Nucleotide/nucleoside estimated to be infected revers

Slide 15: VBI-2601: Potential to be a Critical Component of a Functional Cure
VBI-2601 : Potential to be a Critical Component of a Functional Cure for Chronic HBV Infection Scientific consensus is that a functional cure for HBV is within reach, but will likely require the use of an immunotherapeutic as part of a combination approach A functional cure will likely require the a

Slide 16: VBI-2601 Development Plan & Status
VBI-2601 Development Plan & Status Studies designed & executed in partnership with Brii Biosciences Phase Ib/2a Study Completed in 2021 + Two-part, multi-center, controlled, dose-escalation study (n=44) + Assessed VBI-2601 safety, tolerability, and immunologic antiviral activity in non-cirrhotic pat

Slide 17: Proof of Mechanism: Significant Restoration of Antibody and T Cell Responses
Proof of Mechanism : Significant Restoration of Antibody and T Cell Responses Demonstrated in Phase 1b/2a Study Complete dataset announced at the International Liver Congress 2021 Potent re-stimulation of T cell responses to HBV surface antigens (S, Pre-SI, Pre-S2) seen in 67% (Cohort B n=6/9) and 7

Slide 18: Phase 2 Combination Study: Design
Phase 2 Combination Study : Design n=50 adult, non-cirrhotic patients who received 2 12 months NRTI treatment were randomized across 3 cohorts 00 04 08 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 4 Week NRT! Discontinuation Monitorng® eooeceeee 6 Follow Up ooecee eee eoeoeevoee

Slide 19: Phase 2 Combination Study: Patient Demographics
Phase 2 Combination Study : Patient Demographics ev “a eo Bre Cohort A Cohort C e Mean Age + SD (years) 459+105 476 +9) 453495 Male, n (%) 8 (72.7%) 14 (70.0%) 15 (75.0%) Race, n (%) Asian m1 (100%) 18 (90%) 18 (90.0%) Black or African American ® 2 (10.0%) 1(8.0%) White 0 fe) 1(5.0%) HBeAg Status at

Slide 20: VBI-2601 Well Tolerated in Both Combination Cohorts
VBI-2601 Well Tolerated in Both Combination Cohorts ‘Cohort © ‘Any TEAES 10 (100%) 19 (950%) 20 (100%) Grade 1 TEES 10 (100%) 19 (950%) 17 (850%) ‘Grads 2 TEAES 1(00%) 7 (50%) 6 (80.0%) 2 Grade 3 TEAES o ° 2 (10.0%) BRI-835 Related TEAES 7 (700%) 13 (650%) 10 (500%) + Majority of TEAEs were Grade |

Slide 21: Notable Reductions in S Antigen Seen Across Cohorts
Notable Reductions in S Antigen Seen Across Cohorts Mean (Sb) Change From Baseline (logo U/ml) Week 32 Week 40 z z 2 (siRNA EOT) (Combo E0T) ES 2 g “175 2 & 3 (039) i i i = ere * * * “181 “77 (om) (072) o 8 «© mm a Study Week study Week Basoline HBsAg: 387.3 IU/mL Baseline HBsAg : 6947 1U/ml Baselin

Slide 22: VBI-2601 + siRNA Combination Elicited Robust Restoration of HBV Surface Antibodies
VBI-2601 + siRNA (BRII-835) Combination Elicited Robust Restoration of HBV Surface Antibodies ant IU/L, <21UIL, 2sX<10 IU/L, 10X<100 IU/L 100<X<1000 IU/L. 21000 IU/L Number of participants with anti-HBs titers by W40 High antibody titers 2 10 IU/L induced in 50% (Cohort B pe) ‘and 58% (Cohort C n=I1

Slide 23: VBI-2601 + siRNA Combination Induced Strong S Antigen-Specific T-Cell Responses
VBI-2601 + siRNA Combination Induced Strong S Antigen-Specific T-Cell Responses VBI-2601 with or without co-adjuvant IFN-a generated notable improvements in HBV S Antigen (HBsAg)-specific T-Cell responses compared to siRNA alone T-Cell Response n=7/10_n=7/10 Addition of VBI-2601 in treatment regimen

Slide 24: S Antigen Reductions to LLOQ or Below Achieved in Two Patients
S Antigen Reductions to LLOQ or Below, to an Undetectable Level, Achieved in Two Patients Robust HBV-specific antibody and T-cell responses associated with $ Antigen (HBsAg) reduction observed in both patients Patient 1 (Cohort 8) Patient 2 (Cohort C) Baseline HBsAg : 723 1U/mL. Baseline HBsAg : 776

Slide 25: VBI-2601 Ongoing Partnership & Upcoming Milestones
VBI-2601 Ongoing Partnership & Upcoming Milestones Brii Partnership: + In December 2018, VBI announced a license and collaboration agreement with Brii Biosciences (Brii Bio) to develop a functional cure for Hepatitis B + Upfront : SIIM - $4M upfront payment + $7M equity investment Bri Biosciences +

Slide 26: Coronaviruses
3 Coronaviruses 26

Slide 27: The Virus that Causes COVID-19 Continues to Evolve
The Virus that Causes COVID-19 Continues to Evolve, Leading to Increasing Number of Mutations and Variants of Concerns COVID-19 Astrain of coronavirus first identified in December 2019 in Wuhan, China Since then, as of February 2023, there have been ~675M confirmed cases worldwide, responsible for 6

Slide 28: VBI is Committed to the Long-Term Protection Against Coronaviruses
VBI is Committed to the Long-Term Protection Against Coronaviruses vBI's coronavirus pipeline program (VBI-2900) is designed with the goal of eliciting broad and durable immune responses against COVID-19 and coronaviruses VBI-2901 Trivalent Pan-Coronavirus VBI-2902 Monovatent COVID-I9 VBI-2905 Monov

Slide 29: VBI-2902 Induced Neutralizing Titers Comparable to Approved mRNA Vaccines
In Phase la Clinical Study, VBI-2902 Induced Neutralizing Titers Comparable to Approved mRNA Vaccines After two doses of 5ug, VBI-2902a elicited neutralizing antibody (nAb) responses 4.3X higher than a panel of convalescent sera, without the use of a next-generation adjuvant Neutralizing Activity’ C

Slide 30: Trivalent VBI-2901 Induced Robust Antibody and Neutralizing Titers
Trivalent VBI-2901 Induced Robust Antibody and Neutralizing Titers Against an Extended Panel of Variants VBI-2901 induced higher and more consistent immunogenicity against Beta, Delta, Kappa, and Lambda variants, with evidence for broadening immunity rather than just boosting cross-reactive antibodi

Slide 31: VBI-2900 Program Summary & Next Steps
VBI-2900 Program Summary & Next Steps eVIP Benefits Y strong immune responses when compared to standard recombinants Y — Multivalency allows for broadly reactive vaccines VY Highly potent immunogenicity, comparable to licensed vaccines Proof-of-Concept Data VY towelinical doses (Sug) & no requiremen

Slide 32: Glioblastoma (GBM)
> § Glioblastoma (GBM)

Slide 33: Unique Approach to Immuno-Oncology
Unique Approach to Immuno-Oncology CMV as a Foreign Viral Antigen + 90% of some solid tumors, including glioblastoma (GBM), breast cancers’, and medulloblastomas? are CMV+ tumors + CMVis not causative, but can influence disease progression of CMV+ tumors + Because CMV is so broadly (and differential

Slide 34: Phase 1/2a Study Design & Objectives
Phase 1/2a Study Design & Objectives Two-part, open-label, dose escalation study designed to assess the safety, tolerability, and optimal therapeutic dose level of VBI-1901 in recurrent GBM patients Phase 1 (Part A) : Dose Study Arm 1: Low Dose (n=6) + Enrollment completed December 2018 (n=18) 0.4ug

Slide 35: Tumor Responses Translated to Clinical Benefit in Phase 1/2a High-Dose Cohorts
Tumor Responses Translated to Clinical Benefit in Phase 1/2a High-Dose Cohorts Based upon these rGBM data, U.S. FDA granted Fast Track Designation in June 2021 for VBI-1901 + GM-CSF for the treatment of recurrent GBM patients with first tumor recurrence Tumor Responses 10110ug + GMCs rt A + Part B)

Slide 36: VBI-1901 Unmet Need & Upcoming Milestones
VBI-1901 Unmet Need & Upcoming Milestones GBM Represents a Significant Unmet Medical Need: GBM is the most common primary brain cancer with approximately 14,000 annual diagnoses in the US, and a low median overall survival of 15-18 months after initial diagnosis! There is no standard of care in the

Slide 37: 37
37

Slide 38: VBI Team
VBI Team —Management JES ¢ fe Jott Boxter David E. Anderson, Francisco Diaz-Mitoma, Christopher McNulty Nell Beattio John Dillman Avi Mazaltov President & CEO PhD. MD, PhO. Chief Financial Officer Chief Business Officer Chief Commercial Global Head of Chief Scientific Officer Chief Medical Officer.

Slide 39: VBI Vaccines Global Footprint
VBI Vaccines Global Footprint Ottawa, Canada Research Operations R&D headquarters and facility Rehovot, Israel Manufacturing Facility GMP manufacturing facility for the production of the HBV program candidates Cambridge, MA, USA *——— Corporate Headquarters Central location in biotechnology hub rd .

Slide 40: Summary of Anticipated Upcoming Milestones
Summary of Anticipated Upcoming Milestones Px HBV PreHevbrio (US.) Tx HBV vel-2601 Coronaviruses VBI-290) GBM vel-190} HI 2028 : Following European Commission and UK Medicines and Healthcare products Regulatory Agency (MHRA) approvals, VBI expects to make PreHevbri available in certain European coun

Slide 41: VBI Vaccines Inc.
VBI Vaccines Inc. WW < w Ui Zz S NS Y www.vbivaccines.com
Source: SEC EDGAR · 8-K filed Feb 28, 2023
More decks from VBI Vaccines Inc.
World Vaccine Congress 202411 slides · Apr 3, 2024
Hepatitis B Portfolio Fireside Chat led by Raymond James (February 2023)29 slides · Feb 28, 2023
Investor Presentation (December 2022)37 slides · Dec 27, 2022
Corporate Update (September 2021)11 slides · Sep 29, 2021
Technical Presentation (November 2020)7 slides · Nov 19, 2020
Corporate Update (November 2020)8 slides · Nov 18, 2020